Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 106

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 106
---
 approximately $3,228 thousand for the six months ended June 30, 2025, compared
to a net income of $7,207 thousand for the six months ended June 30, 2024. The increase in net loss was mainly the result
of an increase in finance expense from fair value revaluation and from decrease in income recorded in 2024 as part of research and development
expenses which were a result of Horizon 2020 Program approval.

Year Ended December 31, 2024 Compared to Year Ended December 31, 2023

Research and development expenses

Research and development
expenses decreased by approximately $2,450 thousand or 303.9%, to approximately income of $1,644 thousand for the year ended December
31, 2024, compared to $806 thousand for the year ended December 31, 2023. The decrease resulted mainly from the Horizon 2020 Grant, and
from a decrease in subcontractors’ expenses due to lower research and development activity during 2024 partly offset by an increase
in expenses related to CSL Settlement, which was recorded during 2024.

General and administrative expenses

General and administrative
expenses decreased by approximately $413 thousand, or 36.7%, to approximately $712 thousand for the year ended December 31, 2024, compared
to approximately $1,125 thousand for the year ended December 31, 2023. The decrease resulted mainly from a decrease in professional fees
due to the recognition of prepaid issuance costs associated with the former initial public offering process, recognized as expense following
the entry into the business combination agreement, or BCA, with OceanTech Corp. during the second quarter of 2023 and additional expenses
associated with the BCA.

<div align='center'>66</div>

Finance income (expense)

Finance expenses decreased
by approximately $6,070 thousand, or 275.8%, to approximately $3,869 thousand finance income for the year ended December 31, 2024, compared
to approximately $2,201 thousand finance expense for the year ended December 31, 2023. The decrease resulted mainly from change in fair
value of convertible notes and a change in fair value of warrant liability.

Net income (loss)

Net loss decreased by approximately
$8,933 thousand to approximately $4,801 thousand net income for the year ended December 31, 2024, compared to $4,132 thousand net loss
for the year ended December